Results 111 to 120 of about 28,144 (206)

Disease‐Intrinsic Organising Pneumonia During Biomarker‐Confirmed Ulcerative Colitis Remission

Respirology Case Reports, Volume 14, Issue 9, September 2026.
Organising pneumonia (OP) can occur as a disease‐intrinsic extraintestinal manifestation of ulcerative colitis (UC) during biochemical remission. Drug‐induced aetiology must be systematically excluded before attributing OP to UC. Cryobiopsy‐based ILD diagnoses require expert pathology review when treatment decisions are consequential, as the ...
Rahaf A. Jereisat, Nawras Ibrahim, Maher Dahdel   +2 more
wiley   +1 more source

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome

Kidney Medicine
Rationale & Objective: Venous thromboembolism is a serious complication of nephrotic syndrome (NS). Guidelines recommend prophylactic anticoagulation with warfarin or low molecular weight heparin.
Sarah Kelddal, Erik L. Grove, Camilla L. Duus, Louis B. Nygaard, Tilde Kristensen, Frank H. Mose, Jon W. Gregersen, Anne-Mette Hvas, Henrik Birn   +8 more
doaj   +1 more source

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2015
Background In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE ...
Xianchen Liu, Margot Johnson, Jack Mardekian, Hemant Phatak, John Thompson, Alexander T. Cohen   +5 more
doaj   +1 more source

Implications of apixaban for dental treatments [PDF]

, 2016
Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. Recently, new oral anticoagulants have been introduced as alternatives to warfarin and acenocoumarol.
Curto Aguilera, Adrián, Albaladejo Martínez, Alberto   +1 more
core  

Aktuelle Daten aus dem Versorgungsalltag zu Apixaban

, 2018
Aktuelle Daten zur Antikoagulation mit dem nicht Vitamin-K-abhängigen oralen Antikoagulans (NOAC) Apixaban (Eliquis®) im deutschen Versorgungsalltag liefert die retrospektive Datenbankanalyse CARBOS (1).
Beate Grübler
core   +1 more source

Effect of Medication Intake on Dental Implant‐Related Outcomes—A Scoping Review

Clinical Oral Implants Research, Volume 37, Issue 9, Page 1033-1056, September 2026.
ABSTRACT Objective The objective of this scoping review was to evaluate the effect of systemic medications on dental implant outcomes in medically compromised patients. Material and Methods Electronic and manual searches were conducted for this scoping review.
Alberto Monje, Maria Costanza Soldini, Emilio Couso‐Queiruga, Álvaro Babiano, Vivianne Chappuis   +4 more
wiley   +1 more source

Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma

, 2017
SummaryThe objective was to characterise apixaban pharmacodynamic (PD) activity in umbilical cord (UC), paediatric, and adult plasma. Plasma was obtained from blood samples from six UC donors, 70 paediatric (neonates [birth–≤1 month], infants [>1–≤6 ...
Robert Yetman, Jessie Wang, Yu Barrett, Charles Frost, Robert Adamczyk, Eduardo Ramacciotti, Zhaoqing Wang   +6 more
core   +1 more source

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, Volume 32, Issue 5, Page 1188-1199, September/October 2026.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1525-1534, September 2026.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel, Sabrina Bänsch, Laura Adam, Nathan Fekade, Alessandra Rünger, Tim Zell, Daniel J. Smit, Julian Kött, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Peter Mohr, Alexandra Geusau, Stephan Grabbe, Markus V. Heppt, Ralf Gutzmer, Jochen Utikal, Jan‐Christoph Simon, Sebastian Haferkamp, Laura Susok, Bastian Schilling, Edgar Dippel, Imke von Wasielewski, Jessica C. Hassel, Carola Berking, Stefan W. Schneider, Christoffer Gebhardt   +27 more
wiley   +1 more source

Is Routine Interruption of Direct Oral Anticoagulants Necessary during Colorectal Endoscopic Mucosal Resection and Hot Snare Polypectomy? A Multicenter Propensity‐Matched Study

Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2826-2833, September 2026.
ABSTRACT Background and Aims Colorectal endoscopic mucosal resection (EMR) and hot snare polypectomy (HSP) are high‐bleeding‐risk endoscopic procedures, and most clinical guidelines recommend stopping direct oral anticoagulants (DOACs) temporarily or switching to heparin‐bridging therapy (HBT). However, existing evidence is largely derived from cohorts
Yutaka Okagawa, Masanori Sato, Masahiro Hirakawa, Shogo Miura, Naotaka Hayasaka, Yusuke Tomita, Saki Ameda, Ginji Omori, Shutaro Oiwa, Akira Sakurada, Tomoyuki Abe, Shinya Minami, Tetsuya Sumiyoshi, Yasuhiro Nagaoka, Hiroyuki Hisai, Shinichi Katsuki, Kohichi Takada   +16 more
wiley   +1 more source